JUL-0 7 2006

PTO/SB/82 (04-05)
Approved for use through 11/30/2005. OMB 0851-0035
U.S. Patont and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PADEMARY PADEMARY sperwork Reduction Act of 1995, no persons are required to res

## **REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY CHANGE OF CORRESPONDENCE ADDRESS**

spend to a collection of information unk	esa it displays a valid OMB control nun	iber.
Application Number	10/729,869	
Filing Date	12/05/2003	
First Named Inventor	Fred Mermelstein	
Art Unit	1614	
Examiner Name	KWON, BRIAN YONG S.	
Attorney Docket Number	077350 0162	

l hereby revoke all pre	vious powers o	of attorney given in th	e above-ide	entified appli	cation.		
A Power of Attorne	ey is submitted h	erewith.					
<i>OR</i> ✓ I hereby appoint t	he practitioners	associated with the Cu	stomer Num	nber:	62	2965	
			·				4
Please change the	correspondence	address for the above	-identified a	pplication to:			
The address a Customer Nur	associated with mber: 62965						
OR							╛
Firm or Individual Name							
Address							
City		Sta	60.1		l Zin	1	_
Country		318	ie		Zip		4
Telephone			Email				$\dashv$
I am the:							┥
Applicant/Invento	D <b>r.</b>						
		nterest. See 37 CFR 3 is enclosed. (Form PT					
	SIGNATU	JRE of Applicant or A	ssignee of	Record			1
Signature	Fredh	melshi					
Name Fred H. Memie	elstein	V		· p···			
Date 7	17/06		Telephone	(617) 349-451			┙
NOTE: Signatures of all the inventor signature is required, see below.	ors or assignees of reco	ord of the entire intorost or their	epresentative(a)	are required. Submi	it multiplo	forms if more than one	
Total offo	rms are submitted.						

This collection of information is required by 37 CFR 1.36. The information is required to obtain or rotain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Committee, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Committee for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

President

PTO/S8/96 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner: Mermelstein et al. Application No./Patent No.: 10/729,869 Filed/Issue Date: 12/05/2003 Entitled: NMDA receptor antagonist formulation with reduced neurotoxicity Innovative Drug Delivery Systems, Inc. Corporation (Name of Assignee) (Type of Assignee, e.g., corporation, purtnership, university, government agency, etc.) states that it is: the assignee of the entire right, title, and interest; or 2. an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is\_ in the patent application/patent identified above by virtue of either: A An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_ \_\_\_\_, or for which a copy thereof is attached. OR B. [ A chain of title from the inventor(s), of the patent application/patent identified above; to the current assignee as shown below: . 1. From: Fred H. Mermelstein and Randi Albin To: Innovative Drug Delivery Systems, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 015124 \_, Frame 0032 , or for which a copy thereof is attached. 2. From: Innovative Drug Delivery Systems, Inc. To: Bristol Investment Fund, Ltd. and Trident Growth Fund, L.P. The document was recorded in the United States Patent and Trademark Office at Reel 015365 \_, Frame \_0207 , or for which a copy thereof is attached. 3, From: Bristol Investment Fund, LTD, and Tridont Growth Fund, L.P. To: Innovative Drug Delivery Systems, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 016743 , Frame <u>0671</u> , or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08] The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. Signature Date Fred H. Mermelstein (617) 349-4511 Printed or Typed Name Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.